Company Kura Oncology, Inc.

Equities

KURA

US50127T1097

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
21.33 USD +0.76% Intraday chart for Kura Oncology, Inc. -0.09% +48.33%

Business Summary

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.

Number of employees: 142

Managers

Managers TitleAgeSince
Chief Executive Officer 55 14-08-21
Chief Tech/Sci/R&D Officer 52 20-08-24
Chief Operating Officer 77 19-08-08
Investor Relations Contact - 17-09-30
Comptroller/Controller/Auditor 53 21-05-31
Corporate Officer/Principal - 23-08-13
Corporate Officer/Principal - 20-01-31
General Counsel 53 21-10-17

Members of the board

Members of the board TitleAgeSince
Director/Board Member 60 21-06-02
Director/Board Member 65 15-04-26
Director/Board Member 55 15-10-13
Director/Board Member 61 18-11-05
Chief Executive Officer 55 14-08-21
Director/Board Member 71 19-10-13
Director/Board Member 61 21-07-28

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 76,136,963 72,954,556 ( 95.82 %) 0 95.82 %

Shareholders

NameEquities%Valuation
BVF, Inc.
9.684 %
7,373,228 9.684 % 155 M $
BlackRock Advisors LLC
9.145 %
6,962,795 9.145 % 147 M $
Suvretta Capital Management LLC
9.123 %
6,946,230 9.123 % 146 M $
EcoR1 Capital, LLC
7.627 %
5,806,871 7.627 % 122 M $
Deerfield Management Co. LP (Private Equity)
6.978 %
5,312,733 6.978 % 112 M $
Vanguard Fiduciary Trust Co.
5.303 %
4,037,691 5.303 % 85 M $
Avoro Capital Advisor LLC
3.914 %
2,980,000 3.914 % 63 M $
2,921,810 3.838 % 62 M $
Holocene Advisors, LP
3.201 %
2,437,463 3.201 % 51 M $
Armistice Capital LLC
2.921 %
2,224,000 2.921 % 47 M $

Company contact information

Kura Oncology, Inc.

12730 High Bluff Drive Suite 400

92130, San Diego

+858 500 8800

http://www.kuraoncology.com
address Kura Oncology, Inc.(KURA)